Ibtrozi (taletrectinib), ROS1-positive NSCLC access
Locally advanced or metastatic ROS1-positive non-small cell lung cancer in adults ยท Oncology (ROS1-positive NSCLC)
About Ibtrozi
Ibtrozi (taletrectinib) is an oral next-generation ROS1 tyrosine kinase inhibitor from Nuvation Bio, dosed at 600 mg once daily. It is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), including patients previously treated with a first-generation ROS1 TKI. It earned US FDA approval in 2025.
Taletrectinib was designed to address resistance mutations and CNS progression that limit earlier ROS1 inhibitors, with a tolerability profile aimed at chronic daily dosing in a metastatic-disease setting.
Where Ibtrozi is not yet registered in a patient's home country, Reserve Meds coordinates supply from US specialty wholesalers via Named Patient Program (NPP) and personal-import pathways, against a destination-country prescription and the regulatory paperwork specific to each jurisdiction.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Ibtrozi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ibtrozi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ibtrozi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Ibtrozi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Ibtrozi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Ibtrozi if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Ibtrozi for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ibtrozi through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Ibtrozi. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ibtrozi through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ibtrozi to a patient?
Reserve Meds sources Ibtrozi from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Ibtrozi cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ibtrozi?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.